Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Chief Discovery Officer | November 14, 2022 | November 16, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date November 14, 2022 · Filed November 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 298,541 |
Ending reported balance
After 2022-11-14 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-11-14 · Exercise / conversion · Acquired 50,000 · Balance 280,056 Row 2 · 2022-11-14 · Exercise / conversion · Acquired 50,000 · Balance 330,056 Row 3 · 2022-11-14 · Sale · Disposed 31,515 · Balance 298,541 F1: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $13.86 to $13.92. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| Emp. Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.42 · Expires 2023-01-01 | Direct | 0 |
Reported balance
After 2022-11-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-11-14 · Exercise / conversion · Disposed 50,000 · Balance 0 F2: Annual Employee Option Grant became exercisable in four equal annual installments, beginning on this date. |
| Emp. Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.42 · Expires 2023-01-01 | Direct | 0 |
Reported balance
After 2022-11-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-11-14 · Exercise / conversion · Disposed 50,000 · Balance 0 F3: Retention Employee Stock Option became exercisable in two equal annual installments, beginning on this date. |
Filing footnotes · ownership attribution and instrument terms
F1: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $13.86 to $13.92. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F2: Annual Employee Option Grant became exercisable in four equal annual installments, beginning on this date.
F3: Retention Employee Stock Option became exercisable in two equal annual installments, beginning on this date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 14, 2022 Filed Nov 16, 2022 21:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001127602-22-025761 · form4.xml · derivative · entry 5 Babu Yarlagadda S · CIK 0001452635 · Chief Discovery Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2023-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Retention Employee Stock Option became exercisable in two equal annual installments, beginning on this date. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 21:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001127602-22-025761 · form4.xml · derivative · entry 4 Babu Yarlagadda S · CIK 0001452635 · Chief Discovery Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2023-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Annual Employee Option Grant became exercisable in four equal annual installments, beginning on this date. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 21:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 31,515 | $13.88 | $437,428.20 |
DisclosureSEC source: 0001127602-22-025761 · form4.xml · nonDerivative · entry 3 Babu Yarlagadda S · CIK 0001452635 · Chief Discovery Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,541 F1 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $13.86 to $13.92. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 21:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 50,000 | $1.42 | $71,000.00 |
DisclosureSEC source: 0001127602-22-025761 · form4.xml · nonDerivative · entry 2 Babu Yarlagadda S · CIK 0001452635 · Chief Discovery Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 21:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 50,000 | $1.42 | $71,000.00 |
DisclosureSEC source: 0001127602-22-025761 · form4.xml · nonDerivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Chief Discovery Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 21:24 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 20,000 | $17.16 | $343,200.00 |
DisclosureSEC source: 0001127602-22-008780 · form4.xml · nonDerivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Chief Discovery Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,056 F1 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.05 to $17.27. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:09 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 164,000 | $0.00 Strike: $11.43 | $0.00 |
DisclosureSEC source: 0001127602-21-031134 · form4.xml · derivative · entry 2 Babu Yarlagadda S · CIK 0001452635 · Chief Discovery Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,000 Underlying: Common Stock · 164,000 shares Expires 2031-12-14 F2 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% of each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:09 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-031134 · form4.xml · nonDerivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Chief Discovery Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,056 F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 21:38 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001127602-21-030610 · form4.xml · derivative · entry 3 Babu Yarlagadda S · CIK 0001452635 · Chief Discovery Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,000 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 21:38 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 30,100 | $12.20 | $367,220.00 |
DisclosureSEC source: 0001127602-21-030610 · form4.xml · nonDerivative · entry 2 Babu Yarlagadda S · CIK 0001452635 · Chief Discovery Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,056 F1 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.18 to $12.22. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 21:38 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 62,000 | $4.73 | $293,260.00 |
DisclosureSEC source: 0001127602-21-030610 · form4.xml · nonDerivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Chief Discovery Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:25 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0001127602-21-007295 · form4.xml · derivative · entry 3 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2021-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:25 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 22,431 | $11.53 | $258,629.43 |
DisclosureSEC source: 0001127602-21-007295 · form4.xml · nonDerivative · entry 2 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,156 F1 · security: Shares of Common Stock delivered to the Company to satisfy payment of exercise price and tax withholding in connection with stock option exercise. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:25 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 50,000 | $4.15 | $207,500.00 |
DisclosureSEC source: 0001127602-21-007295 · form4.xml · nonDerivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:30 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 280,000 | $0.00 Strike: $8.31 | $0.00 |
DisclosureSEC source: 0001127602-20-031788 · form4.xml · derivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2030-12-15 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% of each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 21:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001127602-20-030696 · form4.xml · derivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2023-08-08 F1 · date: On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based stock options awarded to the reporting person on August 8, 2013 has been met. Therefore, 25% of such performance-based stock options vested on December 3, 2020. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:42 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-20-007672 · form4.xml · derivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2024-12-22 F1 · date: On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 20% of the performance-based stock options vested. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 22:03 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 31,500 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-20-006501 · form4.xml · derivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2024-12-22 F1 · date: On February 18, 2019, BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted and filed its new drug application for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema attacks. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 35% of the performance-based stock options vested. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 22:52 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001127602-19-035551 · form4.xml · derivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2029-12-17 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 21:03 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | PurchaseCommon Stock | 25,000 | $1.45 | $36,250.00 |
DisclosureSEC source: 0001127602-19-033004 · form4.xml · nonDerivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,587 Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 21:13 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 12,188 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001127602-19-003737 · form4.xml · derivative · entry 6 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,188 shares Expires 2019-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 21:13 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionNon-Qualified Stock Option · Derivative | 19,686 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001127602-19-003737 · form4.xml · derivative · entry 5 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,686 shares Expires 2019-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 21:13 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 1,685 | $8.68 | $14,625.80 |
DisclosureSEC source: 0001127602-19-003737 · form4.xml · nonDerivative · entry 4 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,587 F2 · security: Shares of Common Stock delivered to the Company to satisfy payment of exercise price in connection with stock option exercise. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 21:13 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 12,188 | $1.20 | $14,625.60 |
DisclosureSEC source: 0001127602-19-003737 · form4.xml · nonDerivative · entry 3 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 21:13 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 7,702 | $8.68 | $66,853.36 |
DisclosureSEC source: 0001127602-19-003737 · form4.xml · nonDerivative · entry 2 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,084 F1 · security: Shares of Common Stock delivered to the Company to satisfy payment of exercise price and tax withholding in connection with stock option exercise. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 21:13 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 19,686 | $1.20 | $23,623.20 |
DisclosureSEC source: 0001127602-19-003737 · form4.xml · nonDerivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:36 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 771 | $8.07 | $6,221.97 |
DisclosureSEC source: 0001127602-19-000730 · form4.xml · nonDerivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,100 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2015. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 21:10 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 235,000 | $0.00 Strike: $7.06 | $0.00 |
DisclosureSEC source: 0001127602-18-037173 · form4.xml · derivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,000 Underlying: Common Stock · 235,000 shares Expires 2028-12-20 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 20:48 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 9,378 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001127602-18-010694 · form4.xml · derivative · entry 6 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,378 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 20:48 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionNon-Qualified Stock Option · Derivative | 20,622 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001127602-18-010694 · form4.xml · derivative · entry 5 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,622 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 20:48 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 5,902 | $5.18 | $30,572.36 |
DisclosureSEC source: 0001127602-18-010694 · form4.xml · nonDerivative · entry 4 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,871 F2 · security: Shares of Common Stock delivered to the Company to satisfy payment of exercise price in connection with stock option exercise. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 20:48 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 9,378 | $3.26 | $30,572.28 |
DisclosureSEC source: 0001127602-18-010694 · form4.xml · nonDerivative · entry 3 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 20:48 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 15,223 | $5.18 | $78,855.14 |
DisclosureSEC source: 0001127602-18-010694 · form4.xml · nonDerivative · entry 2 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,395 F1 · security: Shares of Common Stock delivered to the Company to satisfy payment of exercise price and tax withholding in connection with stock option exercise. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 20:48 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 20,622 | $3.26 | $67,227.72 |
DisclosureSEC source: 0001127602-18-010694 · form4.xml · nonDerivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 20, 2018 Filed Jan 23, 2018 14:10 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 3,872 | $5.59 | $21,644.48 |
DisclosureSEC source: 0001127602-18-002235 · form4.xml · nonDerivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,996 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2014. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 14:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 838 | $4.91 | $4,114.58 |
DisclosureSEC source: 0001127602-18-000306 · form4.xml · nonDerivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,868 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2015. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 15:13 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001127602-17-035401 · form4.xml · derivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-12-20 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 19:37 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-17-026938 · form4.xml · derivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2024-12-22 F1 · date: On August 30, 2017, the Science Committee of the Board of Directors determined that the BCX7353 APeX-1 clinical trial met its goals and BCX7353 warrants further development. As a result, on August 31, 2017, the Compensation Committee of the Board of Directors determined that one of the vesting criteria associated with the performance-based stock options awarded in December 2014 to all employees, excluding the Chief Executive Officer, has been met. Therefore, 30% of the performance-based stock options vested on August 31, 2017. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 18:50 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001127602-17-009099 · form4.xml · derivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2027-02-27 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 14:25 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 5,083 | $5.95 | $30,243.85 |
DisclosureSEC source: 0001127602-17-002250 · form4.xml · nonDerivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,706 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's federal and state tax withholding obligations upon the vesting of restricted stock units granted in 2014. Read SEC document |
| January 01, 2017 Filed Jan 3, 2017 19:09 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 1,639 | $6.33 | $10,374.87 |
DisclosureSEC source: 0001127602-17-000077 · form4.xml · nonDerivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,789 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2013 and 2015. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.